Hymecromone Sopharma

Quick links

Choose a section

Quick links to important sections

Advertisements

Hymecromone Sopharma

Advertisements
Advertisements

Method of action: Choleretic

Advertisements

Overview of Hymecromone Sopharma

Quick Facts

Property Description
Active ingredient Hymecromone (7-Hydroxy-4-methylcoumarin)
Form Solid Oral Tablet
Pharmacological Class Choleretic Agent, Biliary Antispasmodic
Common Use Normalizing bile flow and relieving biliary spasm
Origin Synthetic Coumarin Derivative

What is Hymecromone and What Type of Drug is It?

Hymecromone Sopharma is a pharmaceutical product containing the active substance Hymecromone (INN), typically manufactured by Sopharma and utilized in various international markets. Chemically, the compound is identified as a synthetic coumarin derivative that structurally distinguishes itself from anticoagulant coumarins, focusing its therapeutic effects strictly on the biliary system. Pharmacologically, Hymecromone is recognized as a dual-action agent: a specialized choleretic agent and a biliary antispasmodic. This classification ensures its action is specialized for supporting digestive processes via bile management.

Hymecromone acts by increasing the output of bile from the liver (choleretic action). This functionality supports the steady flow of bile and addresses issues associated with its stagnation.


Composition, Form, and General Purpose

The medication is a single-component monotherapy, containing only the active ingredient Hymecromone, and is administered via the oral route, typically supplied as a solid tablet. The core function is rooted in two complementary effects recognized to address biliary tract issues: the stimulation of bile production and the relaxation of smooth muscle in the bile ducts and the sphincter of Oddi (antispasmodic action).

This combination of effects serves the general purpose of restoring and supporting proper bile movement and flow. A typical use scenario involves helping individuals whose digestive discomfort stems from impaired bile transport or functional spasm within the biliary tract, providing a consistent means to deliver this specialized action to the digestive system.

Advertisements

What side effects are possible with Hymecromone Sopharma?

Possible Side Effects and Safety Information

The safety profile of Hymecromone is formally documented in regulatory safety classifications, organizing potential adverse reactions by both frequency and the affected body system, consistent with the principles of official prescribing information.

Adverse Reaction Scope

Category Description (Regulatory Context)
Frequency Classification Common effects include gastrointestinal disturbances, abdominal pain, nausea, vomiting, diarrhea, and headache. Rare effects include hypersensitivity reactions and liver enzyme abnormalities.
System-Organ Classes Effects are primarily categorized under Gastrointestinal Disorders and Nervous System Disorders, with documented reactions also in Hepatobiliary Disorders and Immune System/Skin Disorders.
Serious Adverse Reactions Officially monitored events include Severe Hypersensitivity Reactions (e.g., anaphylaxis) and clinically significant Liver Enzyme Abnormalities.

Safety-Related Restrictions and Constraints

The official labeling includes specific safety considerations that define the appropriate use of Hymecromone. The medicine is contraindicated in patients with a known hypersensitivity to the active substance or with complete or significant biliary obstruction. Additionally, regulatory documents advise caution and potential restriction for use in individuals with severe hepatic (liver) impairment or severe renal (kidney) impairment, and in those with a history of gastrointestinal ulcers or bleeding. High-level safety notes include the potential for an increased risk of bleeding when the medicine is used concurrently with anticoagulants (blood thinners).

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overdose manifestations and required emergency actions for Hymecromone is based strictly on descriptions provided in official government regulatory sources, such as the Summary of Product Characteristics (SmPC).


Documented Overdose Manifestations

Overdosage is primarily associated with an exacerbation of known adverse effects, predominantly affecting the gastrointestinal system. Regulator-listed presentations include gastrointestinal disturbances, such as severe diarrhea and general abdominal distress or discomfort. In cases of significant overexposure, regulatory documentation notes the potential for transient elevation of serum transaminases (liver enzymes), necessitating close observation of the hepatic system.


Emergency Actions and Management

Element Official Regulatory Documentation
Mandated Action Seek immediate medical attention or contact emergency medical services.
Antidote Status No specific antidote is known.
Management Symptomatic and supportive treatment to manage clinical manifestations and monitor vital functions.

Immediate medical care is required upon suspicion of overdose, regardless of the initial severity of symptoms. Due to the lack of a specific antidote, professional supervision is necessary. Regulatory labeling advises that hospital monitoring may be required, particularly to assess and track liver function. The risk of complications may be heightened in patients with pre-existing severe renal or hepatic insufficiency.

Advertisements

Therapeutic Uses of Hymecromone Sopharma

What Hymecromone Sopharma Treats: Main Uses and Benefits

Hymecromone is applied in clinical settings that involve acute or unstable symptom patterns, particularly those within the biliary system. The drug is commonly used in the symptomatic management of conditions characterized by periods of heightened symptoms, which involve recurrent or episodic manifestations. This is applied in situations involving certain distressing symptoms, particularly sharp, cramp-like pain and discomfort associated with biliary functional issues. The use of this medicine may assist with managing symptoms that create noticeable physiological strain by helping to moderate these acute manifestations.


The medication is relevant in contexts marked by increased discomfort due to sluggish bile flow and subsequent congestion, where it is used for managing the related feelings of pressure and fullness that interfere with daily comfort. This supportive action contributes to improved comfort during periods of heightened symptoms and may assist patients with managing symptom fluctuations. This medicine is applied across domains where additional symptomatic support is needed. It supports general well-being during symptomatic phases by easing distress during difficult episodes.

Quick Fact: Relief for Spasmodic Pain and Discomfort in the Biliary Tract

Advertisements

Eligibility and Restrictions for Use

The eligibility for using Hymecromone is strictly defined by official regulatory documentation, which outlines populations who must not use the medicine (contraindications) and those for whom use is restricted or conditional.

Populations Who Must Not Use Hymecromone (Contraindicated)

Individuals who are absolutely excluded from using this medicine include those with:

  • Hypersensitivity (allergy) to the active substance, Hymecromone, or any of the inactive ingredients.
  • Biliary tract obstruction.
  • Acute hepatic failure (sudden, severe liver dysfunction).

Conditional or Not Recommended Use

Population Category Regulatory Status (Official Caution/Restriction)
Children (Pediatric) Not recommended; safety and effectiveness have not been established in this age group.
Severe Renal Impairment Use with caution; special monitoring and potentially dosage adjustments are necessary.
Pregnancy Use is not recommended; limited or no adequate safety data are available.
Breastfeeding Use is not recommended; it is unknown if the substance passes into breast milk and affects the infant.

These official eligibility statements specify that the medicine is reserved for adults who do not have the listed absolute exclusions or severe organ impairments, in line with regulatory classifications from bodies such as the European Medicines Agency (EMA).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following section outlines the documented interactions of Hymecromone Sopharma with other medicinal products, based on official regulatory information. These statements are solely for informational purposes regarding interaction potential and are not clinical advice.

Pharmacodynamic Interactions (Antagonism)

The primary documented interactions for Hymecromone involve antagonism, which is the counteraction or reduction of its therapeutic effect (choleretic and antispasmodic action on the bile duct) when taken alongside certain drugs:

  • Opioid Analgesics (e.g., Morphine): The concurrent use of Hymecromone with Morphine or other substances that cause relaxation of the Sphincter of Oddi may counteract and reduce the beneficial choleretic and antispasmodic effects of Hymecromone.
  • Prokinetics (e.g., Metoclopramide): The therapeutic action of Hymecromone on the biliary tract is reduced by Metoclopramide. This is due to the opposing effects these two medicines have on gastrointestinal muscle tone and motility.

Potential Metabolic Interaction

  • Oral Antidiabetics (Sulfonylurea Derivatives): Hymecromone has been noted to potentially potentiate the action of oral antidiabetic medicines, particularly those belonging to the sulfonylurea class. This potentiation may increase the blood glucose-lowering effect, necessitating careful monitoring.
Advertisements

Mechanism of Action

Hymecromone's effect is driven by two primary mechanistic actions that target the smooth muscle surrounding the bile ducts.

Targeting Smooth Muscle Signaling: Enzyme Inhibition

Hymecromone initiates its mechanism by acting as an inhibitor of specific Phosphodiesterase (PDE) enzymes, particularly those within the biliary tract. This inhibition prevents the breakdown of cyclic nucleotides (e.g., cAMP) inside the smooth muscle cells, which are key second messengers. The resulting accumulation of these messengers triggers a biological sequence that lowers the intracellular concentration of calcium ions ( Ca^2+).

Physiological Consequence: Spasmolysis and Choleresis

The reduction in cellular calcium concentration is the core mechanism that triggers smooth muscle relaxation (spasmolysis) in the bile ducts and the sphincter of Oddi. This action results in reduced resistance to flow through the biliary tract. Additionally, the drug exhibits a choleretic mechanism, resulting in increased bile secretion from the liver itself.

Advertisements

Dosage and Administration Information

Instruction Map: How to Use Hymecromone Sopharma

This map details the administration protocols for Hymecromone, as outlined in prescribing information.

Entity Instruction
Route of administration Oral route, taken by mouth.
Dosing schedule (Adult) The typical total adult daily dose ranges between 1200 mg and 2400 mg.
Timing in relation to meals Administration may be instructed to occur half an hour before meals or with water, depending on specific prescribing information.
Preparation requirements The medicine is taken as a solid oral tablet and is generally not intended to be divided.
Age-group administration rules The primary usage profile and dosing schedule apply to adults. Specific, widely standardized dose modifications for other populations are not consistently detailed in the general usage profile.
Special procedural conditions The medicine is prescribed for short-term, defined courses of treatment.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily use in divided doses, commonly three times per day (TID).
Basis of use Governed primarily by standard health agency protocols.
Use-context constraints Administration is typically confined to defined, short-term courses; timing may be relative to food intake.

Resulting Procedural Structure

The protocol establishes a standardized schedule for taking the medicine. The prescribed dose is taken orally and three times daily, adhering to a defined period of use that lasts for a short duration (e.g., up to 14 days). The specific administration instruction often involves coordinating the tablet intake with meals to ensure proper usage. This structure maintains adherence to the established use protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hymecromone Sopharma


Evidence for Use in Biliary Dyskinesia and Spasm

Hymecromone Sopharma was studied in research contexts involving conditions characterized by fluctuating or episodic manifestations related to the bile ducts. Research has examined the use of Hymecromone Sopharma in settings where symptoms are often acute, focusing on outcomes related to physical discomfort. The evidence suggests findings describe patterns observed in the studies related to patient-reported outcomes describing perceived discomfort in the upper abdomen. These findings were observed in some studies conducted over defined time intervals and reflect group patterns, not personal outcomes. Data for certain groups remain insufficient, and the follow-up durations were limited in much of the available research, meaning long-term certainty about outcomes is still emerging.


Evidence for Use as an Adjuvant in Gallstone Disease

Studies have explored the use of Hymecromone Sopharma alongside other treatments for conditions like chronic cholecystitis or as a supportive agent in the research of gallstone disease. Hymecromone Sopharma was evaluated in research scenarios exploring its use alongside primary therapies for conditions associated with acute or disruptive episodes. These studies generally explored whether the use of the drug was associated with outcomes reflecting daily functioning or activity level in the bile system. While research has monitored its use in these contexts, comparative evidence is lacking to fully understand its impact versus other supportive measures. Sample sizes were modest in some of these trials, and the results apply only to the populations studied.


What is Still Uncertain About Hymecromone Sopharma

Several areas of uncertainty remain regarding Hymecromone Sopharma. Evidence quality varies across studies, leading to mixed findings on certain outcomes. The primary gaps involve the need for more robust comparative evidence to understand how the medication’s observed patterns relate to other available options. Furthermore, long-term effects are not fully established, and limited information exists for long-term outcomes. Research highlights what is known — and what is still uncertain. More large-scale, long-duration trials are needed to increase the overall certainty of the evidence base.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Hymecromone Sopharma (FAQ)


Q: What is Hymecromone Sopharma used for?

A: Hymecromone is a medication that has been authorized for use in the management of biliary spasm (spasms in the biliary tract) and biliary dyskinesia, conditions that relate to the movement of bile.


Q: Is Hymecromone Sopharma a type of painkiller?

A: Hymecromone is classified as an antispasmodic agent. It is intended to help reduce muscle spasms in the biliary system. While this action may lead to the relief of discomfort associated with those spasms, its primary classification is not as a general painkiller.


Q: How does Hymecromone Sopharma work to affect bile flow?

A: The mechanism of action involves a potential antispasmodic effect on the smooth muscles of the bile ducts and the sphincter of Oddi. This may result in a relaxation of these structures, thereby assisting the normal flow of bile from the gallbladder into the intestine.


Q: Does Hymecromone Sopharma have any other studied effects besides the biliary system action?

A: Research studies have explored the compound known as 4-methylumbelliferone, which is the active substance in Hymecromone. Some preclinical and early human studies have suggested that this compound may be associated with the inhibition of hyaluronan synthesis, a component of the body's extracellular matrix. This area of research is considered investigational and is not a part of the drug's established, authorized use.


Q: What are the common possible side effects of Hymecromone Sopharma?

A: As with any medication, use may be associated with side effects. Common reports have included mild gastrointestinal disturbances such as diarrhea or a feeling of fullness/pressure in the abdomen. If you experience unexpected or severe adverse effects, consult a healthcare professional promptly.


Q: Are there any known contraindications for taking Hymecromone Sopharma?

A: This medication is typically not recommended for individuals with a known hypersensitivity or allergy to hymecromone. It is also generally avoided in patients diagnosed with a bile duct obstruction or in cases of severe liver failure.

Advertisements

How should Hymecromone Sopharma be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents outline specific, non-advisory instructions for storing and disposing of Hymecromone Sopharma tablets, focusing on stability, safety, and environmental protection.

Storage and Stability Requirement
Temperature No special temperature precautions are required; store under standard conditions.
Child Safety Keep the medicine out of the sight and reach of children.
Expiration Do not use after the expiry date (EXP) printed on the packaging.

Disposal Instructions

The official label mandates that this medicine must not be disposed of via wastewater or household waste. These rules are in place to help protect the environment.

To dispose of expired or unused Hymecromone Sopharma, you must ask your pharmacist or local waste authority for guidance on proper pharmaceutical waste collection and disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hymecromone Sopharma found in:

A-Z Index: